PDCD1LG2 and neoplasm: To investigate the rate of success of double PDL1 and PDL2 blockade in immunogenic tumors, C57Bl/6 female bearing EG.7-OVA tumors were treated with anti-PDL1 and anti-PDL2 blocking Abs or control IgG diluted in saline as control (Figure 1B) every three/four days starting at day 13 from tumor implant.